Everything below concerns synaptogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-30. Numbers and descriptions here follow the published literature rather than marketing material.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
==== Immunology ==== Serologic tests can help to diagnose autoimmune disorders by identifying abnormal antibodies directed against a person's own tissues (autoantibodies). Several autoantibodies are used as clinical biomarkers to diagnose an autoimmune disease or in differential diagnosis of autoimmune diseases. Also in atopic allergy diseases diagnosis the allergen specific IgE level is measured by a serologic assay. In coeliac disease diagnostics, a study evaluating multiparametric immunoassay Polycheck® Celiac IgA + total IgA reported high sensitivity and specificity for simultaneous measurement of TG2 IgA and total IgA.
=== Unhealthy weight loss === Some unhealthy weight loss illnesses can include cancer, diseases such as liver and kidney disease, diabetes, hyperthyroidism, and eating disorders such as anorexia and bulimia. It is important to know the difference between healthy weight loss and unhealthy weight loss.
Most proteins require some salt to dissolve in water, a process called salting in. As the salt concentration is increased, proteins can precipitate, a process called salting out which involves changing protein solubility. For example, in bulk protein purification, a common first step to isolate proteins is precipitation with ammonium sulfate (NH4)2SO4. This is performed by adding increasing amounts of ammonium sulfate and collecting the different fractions of precipitated protein. Subsequently, ammonium sulfate can be removed using dialysis (separating proteins from small molecules through a semipermeable membrane). During the ammonium sulfate precipitation step, hydrophobic groups present on the proteins are exposed to the atmosphere, attracting other hydrophobic groups; the result is the formation of an aggregate of hydrophobic components. In this case, the protein precipitate will typically be visible to the naked eye. One advantage of this method is that it can be performed inexpensively, even with very large volumes. The first proteins to be purified are water-soluble proteins. Purification of integral membrane proteins requires disruption of the cell membrane in order to isolate any one particular protein from others that are in the same membrane compartment. Sometimes a particular membrane fraction can be isolated first, such as isolating mitochondria from cells before purifying a protein located in a mitochondrial membrane.
==== Glazes ==== Uranium pigments are used to color ceramic tiles with uranium glazes (red, yellow, brown), where 2 mg of uranium per cm2 is allowed. Between 1900 and 1943, large quantities of uranium-containing ceramics were produced in the United States, as well as in Germany and Austria. It is estimated that between 1924 and 1943, 50-150 tons of uranium (V,VI) oxide were used annually in the U.S. to produce uranium-containing glazes. In 1943, the U.S. government imposed a ban on the civilian use of uranium-containing substances, which remained in effect until 1958. Beginning in 1958, the U.S. government, and in 1969 the United States Atomic Energy Commission, sold depleted uranium in the form of uranium(VI) fluoride for civilian use. In Germany, uranium-glazed ceramics were produced by the Rosenthal porcelain factory and were commercially available until the early 1980s. Uranium-glazed ceramics should only be used as collector's items and not for everyday use due to possible abrasion.
Sources: en.wikipedia.org
=== Available forms === Each Contrave tablet contains 8 mg naltrexone and 90 mg bupropion. Once full dosing is reached (after 4 weeks of administration), the total dosage of Contrave for treating overweight or obesity is two tablets twice daily or 32 mg naltrexone and 360 mg bupropion per day.
κ-Bungarotoxin can be extracted from the Bungarus multicinctus venom glands. Upon extraction, the κ-bungarotoxin needs to be isolated and purified for further use. Another way to yield κ-bungarotoxin is by chemically synthesizing the gene which codes for the toxin. Transplanting this gene into Escherichia coli does not result in a stable product. However, after fusing the toxin with rat intestinal fatty acids, the fusion proteins differed only in cleavage sites. Hereafter, the κ-bungarotoxin could be isolated and purified. Further research discovered that an active form of yeast, Pichia pastoris, was able to make biologically active Kappa-Bungarotoxin. This process does not require additional manipulation of genes or proteins. Furthermore, the produced quantity is five times higher than that of E. coli produced κ-bungarotoxin.
=== Tempe kering === Also known as kering tempe (lit: 'dry tempeh'), or sambal goreng tempe if mixed with plenty of hot and spicy sambal chili pepper sauce. It is a crispy, sweet and spicy, fried tempeh. The raw tempeh is cut into small sticks and thoroughly deep-fried until no longer moist, and then mixed with palm sugar, chili pepper or other spices, or with sweet soy sauce. Often it is mixed with separately fried peanuts and anchovies (ikan teri). This dry tempeh will keep for up to a month if cooked and stored properly.
Today, each region in Japan has its own brand of Wagyu beef, numbering more than 320. The first Wagyu beef to gain a reputation was Kobe beef, already famous since the 1860s and known to foreign countries through foreign residents. Ōmi beef also had a reputation since the Meiji era (1868–1912) for its delicious taste. In the Taisho era (1912–1926), Matsusaka beef also became well known. These were originally Tajima cattle, and calves were purchased from the Tajima region, fattened in each region, and then sold. In the Tokyo area, Yonezawa beef has also been known since the Meiji era. Since the 1980s, Wagyu beef branding has been promoted in various regions of Japan. However, the Japanese Trademark Law at the time did not allow for the establishment of regional collective trademarks, which posed a problem in terms of legal protection. Before the Beef Traceability Law (2003) was enacted, there were also issues regarding the verification of the origin, breeding location, and distribution of Wagyu beef. In 2006, the Japanese Trademark Law was amended to recognize regional collective trademarks, allowing Wagyu beef to be registered as a "regional brand." In 2014, the Geographical Indications Law was passed, and the operation of Geographical Indications (GI) protection began in 2015. Currently, the GI-registered brands of Wagyu beef are as follows.
== Usage as doping product == As a performance-enhancing drug, EPO has been banned since the early 1990s, but a test was not available until the 2000 Summer Olympics. Before this test was available, some athletes were sanctioned after confessing to having used EPO, for example in the Festina affair, when a car with doping products for the Festina cycling team was found. The first doping test in cycling was used in the 2001 La Flèche Wallonne. The first rider to test positive in that race was Bo Hamburger, although he was later acquitted because his B-sample was not conclusive. The U.S. Postal Service Pro Cycling Team, under the leadership of Lance Armstrong and Johan Bruyneel, ran a sophisticated doping program that lasted for many years during the late 1990s and early 2000s. Erythropoietin was a common substance used by the cyclists. Studies of the effectiveness of EPO in cycling consistently associate EPO with an increase in subjects' maximal aerobic capacity, but yield mixed results as to the drug's effects on submaximal aerobic efforts. A 2007 study showed that EPO treatment led to a statistically significant improvement in cyclists' abilities to maintain a "submaximal" effort of about 80% of their pre-treatment aerobic maximum (VO2max). The study found that subjects treated with EPO saw increased VO2max values, and the amount of time they could maintain their initial submaximal effort also increased.
Sources: en.wikipedia.org
=== Legal status === Eflornithine, sold under the brand name Vaniqa, was granted marketing approval by the US FDA, the European Commission among others, is a topical prescription treatment that slows the growth of facial hair. Ornidyl, the injectable form of eflornithine hydrochloride, is licensed by Sanofi-Aventis, and is discontinued in the US. In July 2025, Norgine B.V. withdrew its application in the European Union for a marketing authorization of Ifinwil for the treatment of people with high-risk neuroblastoma (cancer of nerve cells in different parts of the body).
== Chemistry == The chemical structure of ACD856 has not yet been disclosed as of 2024, but the structure of its predecessor ponazuril (ACD855) is known and both ponazuril and ACD856 have been described as triazinetriones.
== Applications == Estimation of the size of DNA molecules following restriction enzyme digestion, e.g. in restriction mapping of cloned DNA. Analysis of PCR products, e.g. in molecular genetic diagnosis or genetic fingerprinting Separation of restricted genomic DNA prior to Southern transfer, or of RNA prior to Northern transfer. Gel electrophoresis is used in forensics, molecular biology, genetics, microbiology and biochemistry. The results can be analyzed quantitatively by visualizing the gel with UV light and a gel imaging device. The image is recorded with a computer-operated camera, and the intensity of the band or spot of interest is measured and compared against standard or markers loaded on the same gel. The measurement and analysis are mostly done with specialized software. Depending on the type of analysis being performed, other techniques are often implemented in conjunction with the results of gel electrophoresis, providing a wide range of field-specific applications.
=== Electrochemical === Polarized liquid interfaces have been used to examine the thermodynamics and kinetics of the transfer of charged species from one phase to another. Two main methods exist. The first is ITIES, "interfaces between two immiscible electrolyte solutions". The second is droplet experiments. Here a reaction at a triple interface between a conductive solid, droplets of a redox active liquid phase and an electrolyte solution have been used to determine the energy required to transfer a charged species across the interface.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.